Literature DB >> 7151703

An education program that improves the psychomotor skills needed for metaproterenol inhaler use.

K A O'Bey, L K Jim, J P Gee, M E Cowen, A E Quigley.   

Abstract

This is the first report assessing an education program's impact on teaching patients the psychomotor skills needed for proper use of the metaproterenol inhaler. Most patients do not use pressurized inhalers correctly. This inability could lead to suboptimal or ineffective therapy. Pharmacists provided a standardized education program to asthma patients and to those with chronic obstructive pulmonary disease for three clinic visits. Proper use of the inhaler was assessed by evaluating the patient's psychomotor performance for each visit before and after instruction. Of 19 patients, 18 demonstrated a mean improvement of 33.5 percent from preinstruction to postinstruction evaluation at the first visit (Student's t-test, p less than 0.0005). Both preinstruction and postinstruction scores demonstrated an upward trend for all three visits, the postinstruction scores always being higher than the preinstruction scores. These results indicate that our standardized education program helped improve psychomotor performance. Certain instructional aspects that need emphasis in future education programs have been identified.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7151703     DOI: 10.1177/106002808201601209

Source DB:  PubMed          Journal:  Drug Intell Clin Pharm        ISSN: 0012-6578


  2 in total

1.  Metered-dose inhaler technique among healthcare providers practising in Oman.

Authors:  Sawsan A Baddar; Omar A Al-Rawas; Kassim A Al-Riyami; Elizabeth A Worthing; Yolande I Hanssens; Aqeela M Taqi; Bazdawi M S Al-Riyami
Journal:  J Sci Res Med Sci       Date:  2001-04

Review 2.  Objectives, methods and content of patient education programmes for adults with asthma: systematic review of studies published between 1979 and 1998.

Authors:  P Sudre; S Jacquemet; C Uldry; T V Perneger
Journal:  Thorax       Date:  1999-08       Impact factor: 9.139

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.